First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Paitients
by on Friday, July 20th, 2012 | No Comments
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Icotinib
Sponsors: Zhejiang Beta Pharma Inc.; Zhejiang Beta Pharma Inc.
Recruiting – verified July 2012
More: First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Paitients